Amgen Inc. (Amgen)

• 2019 The targetable kinase PIM1 drives ALK inhibitor resistance in high-risk neuroblastoma independent of MYCN status

Download
 RDF/XML-Format
 JSON-LD-Format
 Turtle-Format
 N3-Format